Page last updated: 2024-12-05

bromoethane

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

bromoethane : A bromoalkane that is ethane carrying a bromo substituent. It is an alkylating agent used as a chemical intermediate in various organic syntheses. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID6332
CHEMBL ID156378
CHEBI ID47232
SCHEMBL ID2322
SCHEMBL ID2319234
MeSH IDM0113023

Synonyms (75)

Synonym
BBX ,
1-bromoethane
ethyl bromide
nsc8824
monobromoethane
bromoethane
wln: e2
etylu bromek
nsc-8824
halon 2001
nci-c55481
bromic ether
74-96-4
ethane, bromo-
hydrobromic ether
bromure d'ethyle
bromodiborane
ethylbromide
inchi=1/c2h5br/c1-2-3/h2h2,1h
1-bromo-ethane
NCGC00091117-01
bromoethane (ethyl bromide)
etylu bromek [polish]
ai3-04462
einecs 200-825-8
un1891
nci-554813
ccris 2504
nsc 8824
hsdb 532
bromoethane, reagentplus(r), >=99%
bromoethane, reagent grade, 98%
B0588
AKOS000118754
bromo-ethane
ethylbromidium
CHEMBL156378
NCGC00091117-02
C19354
cas-74-96-4
NCGC00257909-01
dtxcid60199
tox21_200355
dtxsid6020199 ,
unii-li8384t9ph
li8384t9ph ,
ethyl bromide [un1891] [poison]
ec 200-825-8
FT-0623246
SCHEMBL2322
ethyl bromide [hsdb]
bromoethane [iarc]
ethyl bromide [mi]
SCHEMBL2319234
1-bromethane
bromo ethane
2-ethyl bromide
ch3ch2br
et-br
c2h5br
1-bromo ethane
un 1891
23705-69-3
F0001-1861
mfcd00000232
CS-D1408
Q412245
STL197475
bromoethane-1,2,2-d3
BS-43810
CHEBI:47232 ,
EN300-19276
ethane-1,1,1-d3, 2-bromo-
bromoethanum
bromoethane (iarc)

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" Generally, the brain tumor responses were considered equivocal, because the characteristics of potential neurocarcinogenic agents (such as statistically significant increased incidences, decreased latency and/or survival, and demonstration of dose-response relationships) were not observed."( Examination of low-incidence brain tumor responses in F344 rats following chemical exposures in National Toxicology Program carcinogenicity studies.
Boorman, GA; Hailey, JR; Haseman, JK; Melnick, RL; Neal, J; Sills, RC,
)
0.13
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (5)

RoleDescription
carcinogenic agentA role played by a chemical compound which is known to induce a process of carcinogenesis by corrupting normal cellular pathways, leading to the acquistion of tumoral capabilities.
solventA liquid that can dissolve other substances (solutes) without any change in their chemical composition.
refrigerantA substance used in a thermodynamic heat pump cycle or refrigeration cycle that undergoes a phase change from a gas to a liquid and back. Refrigerants are used in air-conditioning systems and freezers or refrigerators and are assigned a "R" number (by ASHRAE - formerly the American Society of Heating, Refrigerating and Air Conditioning Engineers), which is determined systematically according to their molecular structure.
local anaestheticAny member of a group of drugs that reversibly inhibit the propagation of signals along nerves. Wide variations in potency, stability, toxicity, water-solubility and duration of action determine the route used for administration, e.g. topical, intravenous, epidural or spinal block.
alkylating agentHighly reactive chemical that introduces alkyl radicals into biologically active molecules and thereby prevents their proper functioning. It could be used as an antineoplastic agent, but it might be very toxic, with carcinogenic, mutagenic, teratogenic, and immunosuppressant actions. It could also be used as a component of poison gases.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
bromoalkaneAny haloalkane that consists of an alkane substituted by at least one bromine atom.
bromohydrocarbonA compound derived from a hydrocarbon by replacing a hydrogen atom with a bromine atom.
volatile organic compoundAny organic compound having an initial boiling point less than or equal to 250 degreeC (482 degreeF) measured at a standard atmospheric pressure of 101.3 kPa.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (9)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
RAR-related orphan receptor gammaMus musculus (house mouse)Potency43.93810.006038.004119,952.5996AID1159521
AR proteinHomo sapiens (human)Potency50.11870.000221.22318,912.5098AID588515
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency39.81070.011212.4002100.0000AID1030
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency55.77560.000214.376460.0339AID720692
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency49.29940.003041.611522,387.1992AID1159552; AID1159555
estrogen nuclear receptor alphaHomo sapiens (human)Potency1.11260.000229.305416,493.5996AID743075
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency50.11870.001019.414170.9645AID588537
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency42.16320.000627.21521,122.0200AID720636
Nuclear receptor ROR-gammaHomo sapiens (human)Potency133.33200.026622.448266.8242AID651802
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (13)

Processvia Protein(s)Taxonomy
negative regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
xenobiotic metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of glucose metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of steroid metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
intracellular receptor signaling pathwayNuclear receptor ROR-gammaHomo sapiens (human)
circadian regulation of gene expressionNuclear receptor ROR-gammaHomo sapiens (human)
cellular response to sterolNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of circadian rhythmNuclear receptor ROR-gammaHomo sapiens (human)
regulation of fat cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of DNA-templated transcriptionNuclear receptor ROR-gammaHomo sapiens (human)
adipose tissue developmentNuclear receptor ROR-gammaHomo sapiens (human)
T-helper 17 cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (10)

Processvia Protein(s)Taxonomy
RNA polymerase II cis-regulatory region sequence-specific DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
protein bindingNuclear receptor ROR-gammaHomo sapiens (human)
oxysterol bindingNuclear receptor ROR-gammaHomo sapiens (human)
zinc ion bindingNuclear receptor ROR-gammaHomo sapiens (human)
ligand-activated transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
sequence-specific double-stranded DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
nuclear receptor activityNuclear receptor ROR-gammaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (4)

Processvia Protein(s)Taxonomy
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
nucleoplasmNuclear receptor ROR-gammaHomo sapiens (human)
nuclear bodyNuclear receptor ROR-gammaHomo sapiens (human)
chromatinNuclear receptor ROR-gammaHomo sapiens (human)
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (39)

Assay IDTitleYearJournalArticle
AID658586Inhibition of Multidrug resistance efflux pump in Mycobacterium smegmatis mc2 155 assessed as inhibition of EtBr efflux measuring normalized fluorescence at half the MIC measured for 60 mins by spectrophotometry relative to control2012Bioorganic & medicinal chemistry, Apr-15, Volume: 20, Issue:8
Compounds of Alpinia katsumadai as potential efflux inhibitors in Mycobacterium smegmatis.
AID531120Antimicrobial activity against Staphylococcus aureus CB1947 harboring rpoB R484H, L520 deficient gyrA, gyrA S48L, gyrA E88K, R236 duplicated parC, parCH103Y, parC S80Y, parC E84G mutant genes selected after CBR-2092 exposure for 20 days2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: studies of the mode of action in Staphylococcus aureus.
AID531132Antimicrobial activity against Staphylococcus aureus CB1953 harboring rpoB H481Y, gyrA S84L, gyrA V598I, parC S80F, parC R570H mutant genes selected after CBR-2092 exposure for 7 days2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: studies of the mode of action in Staphylococcus aureus.
AID220343Apparent binding constant to calf thymus DNA was evaluated by measuring the loss of ethidium fluorescence1993Journal of medicinal chemistry, Apr-02, Volume: 36, Issue:7
In vitro cytotoxicity of GC sequence directed alkylating agents related to distamycin.
AID530917Antimicrobial activity against Staphylococcus aureus CB18842008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: studies of the mode of action in Staphylococcus aureus.
AID571768Antimicrobial activity against Escherichia coli K-12 3-AG300 harboring AcrB-I626M mutant gene2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Site-directed mutagenesis reveals amino acid residues in the Escherichia coli RND efflux pump AcrB that confer macrolide resistance.
AID531123Antimicrobial activity against Staphylococcus aureus CB814 harboring gyrA S48L and parC S80F mutant genes2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: studies of the mode of action in Staphylococcus aureus.
AID531129Antimicrobial activity against Staphylococcus aureus CB815 harboring rpoB H481Y, gyrA S48L and parC S80F mutant genes2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: studies of the mode of action in Staphylococcus aureus.
AID658581Inhibition of Multidrug resistance efflux pump in Mycobacterium smegmatis mc2 155 assessed as EtBr accumulation measuring relative fluorescence at half the MIC measured for 60 mins by spectrophotometry relative to control2012Bioorganic & medicinal chemistry, Apr-15, Volume: 20, Issue:8
Compounds of Alpinia katsumadai as potential efflux inhibitors in Mycobacterium smegmatis.
AID571927Ratio of MIC for Escherichia coli K-12 3-AG300 harboring acrB::rpsLneo mutant gene to MIC for Escherichia coli K-12 3-AG3002009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Site-directed mutagenesis reveals amino acid residues in the Escherichia coli RND efflux pump AcrB that confer macrolide resistance.
AID571884Antibacterial activity against Escherichia coli KAM32 harboring recombinant plasmid pVBS1 encoding Acinetobacter baumannii abeS gene by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Role of AbeS, a novel efflux pump of the SMR family of transporters, in resistance to antimicrobial agents in Acinetobacter baumannii.
AID304719Binding affinity to calf thymus dodecamer DNA assessed as thermal stability in cacodylate buffer containing 0.1 M NaCl at 12 uM2007Journal of medicinal chemistry, Dec-27, Volume: 50, Issue:26
Amine-guanidine switch: a promising approach to improve DNA binding and antiproliferative activities.
AID571766Antimicrobial activity against Escherichia coli K-12 3-AG300 harboring AcrB-615-628MexB-N616 mutant gene2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Site-directed mutagenesis reveals amino acid residues in the Escherichia coli RND efflux pump AcrB that confer macrolide resistance.
AID571926Antimicrobial activity against Escherichia coli K-12 3-AG300 harboring AcrB-N623S-Q624S mutant gene2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Site-directed mutagenesis reveals amino acid residues in the Escherichia coli RND efflux pump AcrB that confer macrolide resistance.
AID531135Antimicrobial activity against Staphylococcus aureus CB1954 harboring rpoB H481Y, gyrA S84L, K809 deficient gyrA, parC S80F, parC A523D mutant genes selected after CBR-2092 exposure for 7 days2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: studies of the mode of action in Staphylococcus aureus.
AID572062Antibacterial activity against abeS sigma abeS-deficient Acinetobacter baumannii AC0037 by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Role of AbeS, a novel efflux pump of the SMR family of transporters, in resistance to antimicrobial agents in Acinetobacter baumannii.
AID531126Antimicrobial activity against Staphylococcus aureus CB1952 harboring rpoB S486L, gyrA S48L, gyrA E88Q, gyrA G532S, parC S80F, parC E84L mutant genes selected after CBR-2092 exposure for 21 days2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: studies of the mode of action in Staphylococcus aureus.
AID571882Antibacterial activity against Escherichia coli KAM32 harboring plasmid pUC18 by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Role of AbeS, a novel efflux pump of the SMR family of transporters, in resistance to antimicrobial agents in Acinetobacter baumannii.
AID1186192Induction of conformational changes in calf thymus DNA assessed as B-DNA conformation changes at 150 uM after 2 hrs by CD spectroscopy2014European journal of medicinal chemistry, Oct-06, Volume: 85Synthesis and biological evaluation of andrographolide analogues as anti-cancer agents.
AID304717Binding affinity to calf thymus DNA assessed as thermal stability in BPE buffer at 2 uM2007Journal of medicinal chemistry, Dec-27, Volume: 50, Issue:26
Amine-guanidine switch: a promising approach to improve DNA binding and antiproliferative activities.
AID658437Antibacterial activity against Mycobacterium smegmatis mc2 155 after 72 hrs by MTT assay2012Bioorganic & medicinal chemistry, Apr-15, Volume: 20, Issue:8
Compounds of Alpinia katsumadai as potential efflux inhibitors in Mycobacterium smegmatis.
AID531117Antimicrobial activity against Staphylococcus aureus CB370 harboring rpoB H481Y mutant gene2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: studies of the mode of action in Staphylococcus aureus.
AID571767Antimicrobial activity against Escherichia coli K-12 3-AG300 harboring AcrB-615-628MexB-M626I mutant gene2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Site-directed mutagenesis reveals amino acid residues in the Escherichia coli RND efflux pump AcrB that confer macrolide resistance.
AID531114Antimicrobial activity against Staphylococcus aureus CB1887 harboring rpoB R484H, L520 deficient gyrA, gyrA S48L, R236 duplicated parC and parC H103Y mutant genes selected after ABT-719 exposure for 20 days2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: studies of the mode of action in Staphylococcus aureus.
AID572059Antibacterial activity against Acinetobacter baumannii AC0037 by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Role of AbeS, a novel efflux pump of the SMR family of transporters, in resistance to antimicrobial agents in Acinetobacter baumannii.
AID571925Antimicrobial activity against Escherichia coli K-12 3-AG300 harboring AcrB-G616N mutant gene2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Site-directed mutagenesis reveals amino acid residues in the Escherichia coli RND efflux pump AcrB that confer macrolide resistance.
AID208559Apparent binding constant to T4 coliphage DNA was evaluated by measuring the loss of ethidium fluorescence1993Journal of medicinal chemistry, Apr-02, Volume: 36, Issue:7
In vitro cytotoxicity of GC sequence directed alkylating agents related to distamycin.
AID571763Antimicrobial activity against Escherichia coli K-12 3-AG300 harboring AcrB-F628F mutant gene2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Site-directed mutagenesis reveals amino acid residues in the Escherichia coli RND efflux pump AcrB that confer macrolide resistance.
AID571931Antimicrobial activity against Escherichia coli K-12 3-AG300 harboring AcrB-615-628MexB-S623N mutant gene2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Site-directed mutagenesis reveals amino acid residues in the Escherichia coli RND efflux pump AcrB that confer macrolide resistance.
AID225774Apparent binding constant to poly (dG.dC) DNA was evaluated by measuring the loss of ethidium fluorescence1993Journal of medicinal chemistry, Apr-02, Volume: 36, Issue:7
In vitro cytotoxicity of GC sequence directed alkylating agents related to distamycin.
AID304718Binding affinity to calf thymus dodecamer DNA assessed as thermal stability in cacodylate buffer at 12 uM2007Journal of medicinal chemistry, Dec-27, Volume: 50, Issue:26
Amine-guanidine switch: a promising approach to improve DNA binding and antiproliferative activities.
AID19825Partition coefficient (logP)1995Journal of medicinal chemistry, Feb-17, Volume: 38, Issue:4
Molecular similarity matrices and quantitative structure-activity relationships: a case study with methodological implications.
AID657780Inhibition of recombinant human topoisomerase 1-mediated unwinding of supercoiled plasmid DNA assessed as DNA intercalation after 2 hrs by gel electrophoresis2012European journal of medicinal chemistry, Jun, Volume: 52Imidazonaphthyridine systems (part 2): Functionalization of the phenyl ring linked to the pyridine pharmacophore and its replacement by a pyridinone ring produces intriguing differences in cytocidal activity.
AID572058Ratio of MIC for Escherichia coli KAM32 harboring plasmid pUC18 to MIC for Escherichia coli KAM32 harboring recombinant plasmid pVBS1 encoding Acinetobacter baumannii abeS gene2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Role of AbeS, a novel efflux pump of the SMR family of transporters, in resistance to antimicrobial agents in Acinetobacter baumannii.
AID571765Antimicrobial activity against Escherichia coli K-12 3-AG300 harboring AcrB-615-628MexB mutant gene2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Site-directed mutagenesis reveals amino acid residues in the Escherichia coli RND efflux pump AcrB that confer macrolide resistance.
AID225772Apparent binding constant to poly (dA.dT) DNA was evaluated by measuring the loss of ethidium fluorescence1993Journal of medicinal chemistry, Apr-02, Volume: 36, Issue:7
In vitro cytotoxicity of GC sequence directed alkylating agents related to distamycin.
AID572061Ratio of MIC for Acinetobacter baumannii AC0037 to MIC for abeS-deficient Acinetobacter baumannii AC00372009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Role of AbeS, a novel efflux pump of the SMR family of transporters, in resistance to antimicrobial agents in Acinetobacter baumannii.
AID572060Antibacterial activity against abeS-deficient Acinetobacter baumannii AC0037 by CLSI broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Role of AbeS, a novel efflux pump of the SMR family of transporters, in resistance to antimicrobial agents in Acinetobacter baumannii.
AID571764Antimicrobial activity against Escherichia coli K-12 3-AG300 harboring acrB::rpsLneo mutant gene2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Site-directed mutagenesis reveals amino acid residues in the Escherichia coli RND efflux pump AcrB that confer macrolide resistance.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (28)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (10.71)18.7374
1990's5 (17.86)18.2507
2000's12 (42.86)29.6817
2010's8 (28.57)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 66.31

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index66.31 (24.57)
Research Supply Index3.50 (2.92)
Research Growth Index4.74 (4.65)
Search Engine Demand Index108.18 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (66.31)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (6.25%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other30 (93.75%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]